Literature DB >> 19586801

Immunoregulatory effects of HO-1: how does it work?

Miguel P Soares1, Ivo Marguti, Andreia Cunha, Rasmus Larsen.   

Abstract

The heme-catabolizing enzyme heme oxygenase-1 (HO-1; encoded by the Hmox1 gene) inhibits the pathogenesis of several immune-mediated inflammatory diseases. This unusually broad salutary effect is thought to rely on the immunoregulatory actions of HO-1, exerted on innate and adaptive immune cells. According to this notion, HO-1 'dampens' innate and adaptive immune responses, limiting immune-mediated tissue injury and thus suppressing the pathogenesis of immune-mediated inflammatory diseases. We will argue that the salutary effects of HO-1 are also exerted via its cytoprotective action, which sustains tissue function and prevents unfettered immune activation by endogenous proinflammatory ligands released from injured cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19586801     DOI: 10.1016/j.coph.2009.05.008

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  44 in total

1.  Heme oxygenase system in hepatic ischemia-reperfusion injury.

Authors:  James A Richards; Stephen J Wigmore; Luke R Devey
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

2.  Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

Authors:  Qing Qing Wu; Yanxia Wang; Martin Senitko; Colin Meyer; W Christian Wigley; Deborah A Ferguson; Eric Grossman; Jianlin Chen; Xin J Zhou; John Hartono; Pamela Winterberg; Bo Chen; Anapam Agarwal; Christopher Y Lu
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-02

3.  Cytoprotection behind heme oxygenase-1 in renal diseases.

Authors:  Matheus Correa-Costa; Mariane Tami Amano; Niels Olsen Saraiva Câmara
Journal:  World J Nephrol       Date:  2012-02-06

Review 4.  Heme oxygenase-1 as a therapeutic target in inflammatory disorders of the gastrointestinal tract.

Authors:  Vijith Vijayan; Sebastian Mueller; Eveline Baumgart-Vogt; Stephan Immenschuh
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

Review 5.  The Iron age of host-microbe interactions.

Authors:  Miguel P Soares; Günter Weiss
Journal:  EMBO Rep       Date:  2015-10-16       Impact factor: 8.807

6.  Heme oxygenase-1 ameliorates dextran sulfate sodium-induced acute murine colitis by regulating Th17/Treg cell balance.

Authors:  Liya Zhang; Yanjie Zhang; Wenwei Zhong; Caixia Di; Xiaoliang Lin; Zhenwei Xia
Journal:  J Biol Chem       Date:  2014-08-11       Impact factor: 5.157

Review 7.  Therapeutic cancer vaccines in combination with conventional therapy.

Authors:  Mads Hald Andersen; Niels Junker; Eva Ellebaek; Inge Marie Svane; Per Thor Straten
Journal:  J Biomed Biotechnol       Date:  2010-06-29

8.  Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter.

Authors:  Yohann Repessé; Ivan Peyron; Jordan D Dimitrov; Suryasarathi Dasgupta; Elika Farrokhi Moshai; Catherine Costa; Annie Borel-Derlon; Benoit Guillet; Roseline D'Oiron; Achille Aouba; Chantal Rothschild; Johannes Oldenburg; Anna Pavlova; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

9.  The microglial α7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2.

Authors:  Esther Parada; Javier Egea; Izaskun Buendia; Pilar Negredo; Ana C Cunha; Silvia Cardoso; Miguel P Soares; Manuela G López
Journal:  Antioxid Redox Signal       Date:  2013-02-25       Impact factor: 8.401

10.  Withania somnifera and Its Withanolides Attenuate Oxidative and Inflammatory Responses and Up-Regulate Antioxidant Responses in BV-2 Microglial Cells.

Authors:  Grace Y Sun; Runting Li; Jiankun Cui; Mark Hannink; Zezong Gu; Kevin L Fritsche; Dennis B Lubahn; Agnes Simonyi
Journal:  Neuromolecular Med       Date:  2016-05-21       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.